MerTK inhibition by either shRNA or treatment with UNC2250 apparently suppressed oncogenic potential in MCL cells, delayed disease progression in MCL-cell-derived xenograft models, and prompted chemosensitivity to vincristine and doxorubicin in vitro or in vivo. Here, MERTK is linked to mantle cell lymphoma.